A carregar...
Transient asymptomatic pulmonary opacities occurring during osimertinib treatment
INTRODUCTION: Osimertinib is an Epidermal Growth Factor Receptor (EGFR) Inhibitor licensed for the treatment of EGFR mutant, T790M positive, non-small cell lung cancer (NSCLC). Previously unreported, common, transient asymptomatic pulmonary opacities (TAPOs) were noted at the University of Colorado...
Na minha lista:
| Publicado no: | J Thorac Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5353353/ https://ncbi.nlm.nih.gov/pubmed/27618759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2016.08.144 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|